NEW YORK--(BUSINESS WIRE)---- $PRGO #classactionlawsuit--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Perrigo Company plc ("Perrigo†or the "Company†) (NYSE:PRGO) securities during the period of February 27, 2023 through November 4, 2025, inclusive ("the Class Period†). If you suffered a loss on your Perrigo investments, you have until January 16, 2026 to request lead plaintiff appointment. For more information: [CONTACT THE ...

Core Viewpoint - Rosen Law Firm is urging investors of Perrigo Company plc to secure legal counsel before the January 16, 2026 deadline for a securities class action lawsuit related to the company's performance during the specified class period [2][4]. Group 1: Class Action Details - The class period for the securities class action is from February 27, 2023, to November 4, 2025 [2]. - Investors who purchased Perrigo securities during this period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [3]. - A class action lawsuit has already been filed, and interested parties must act by the January 16, 2026 deadline to serve as lead plaintiff [4]. Group 2: Reasons for Legal Counsel - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience and resources [5]. - The firm has a history of significant recoveries for investors, including over $438 million in 2019 alone, and has been recognized for its success in securities class action settlements [5]. Group 3: Case Allegations - The lawsuit alleges that Perrigo made materially false and misleading statements regarding its infant formula business, including underinvestment in maintenance and the need for substantial capital expenditures [6]. - It is claimed that these misrepresentations led to overstated financial results, affecting earnings and cash flow, and that the true state of the business caused investor damages when revealed [6].

Core Viewpoint - A class action securities lawsuit has been filed against Perrigo Company plc, alleging securities fraud that affected investors between February 27, 2023, and November 4, 2025 [1][2]. Group 1: Allegations of Fraud - The lawsuit claims that Perrigo's infant formula business, acquired from Nestlé, suffered from significant underinvestment in maintenance and operational improvements [2]. - It is alleged that Perrigo needed to incur substantial capital and operational expenditures beyond previously stated cost estimates to address issues in the infant formula business [2]. - The complaint highlights significant manufacturing deficiencies in the facility dedicated to the infant formula business [2]. - As a result of these issues, Perrigo's financial results, including earnings and cash flow, were reportedly overstated [2]. - The positive statements made by the defendants regarding the Company's business and prospects were claimed to be materially misleading and lacked a reasonable basis [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until January 16, 2026, to request appointment as lead plaintiff [3]. - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4].

Core Viewpoint - A class action lawsuit has been filed against Perrigo Company plc for violations of federal securities laws, impacting investors who acquired securities between February 27, 2023, and November 4, 2025 [1] Group 1: Allegations Against Perrigo - The lawsuit alleges that Perrigo and certain officers made false or misleading statements regarding the infant formula business acquired from Nestlé, which suffered from significant underinvestment in maintenance and operational improvements [2] - It is claimed that Perrigo needed to incur substantial capital and operational expenditures beyond previously stated cost estimates to address issues in the infant formula business [2] - The complaint highlights significant manufacturing deficiencies in the facility for the infant formula business, leading to overstated financial results, including earnings and cash flow [2] - As a result of these issues, the positive statements made by Perrigo regarding its business and prospects were materially misleading [2] Group 2: Impact on Investors - Following the revelation of these issues, Perrigo's common stock experienced a significant decline, resulting in financial losses for investors [3] - Investors who suffered losses exceeding $150,000 in Perrigo's securities are encouraged to participate in the lawsuit or learn more about the lead plaintiff process [3] Group 3: About the Law Firm - Lowey Dannenberg P.C. is a national law firm that represents institutional and individual investors who have suffered financial losses due to corporate fraud and violations of federal securities laws [4] - The firm has a strong track record in prosecuting multi-million-dollar lawsuits and has recovered billions for its clients [4]

Core Points - Class action lawsuits have been filed on behalf of shareholders of several publicly-traded companies, with specific deadlines for filing lead plaintiff motions [1][2][3][4]. Group 1: Freeport-McMoran Inc. (NYSE: FCX) - The class period for Freeport-McMoran is from February 15, 2022, to September 24, 2025, with a lead plaintiff deadline of January 12, 2026 [2]. - Allegations include failure to ensure safety at the Grasberg Block Cave mine in Indonesia, leading to heightened risks for workers and misleading positive statements about the company's operations [2]. Group 2: Perrigo Company plc (NYSE: PRGO) - The class period for Perrigo is from February 27, 2023, to November 4, 2025, with a lead plaintiff deadline of January 16, 2026 [3]. - The complaint alleges significant underinvestment in the infant formula business acquired from Nestlé, requiring substantial capital expenditures and resulting in overstated financial results [3]. Group 3: StubHub Holdings, Inc. (NYSE: STUB) - The class period for StubHub is from its September 2025 IPO, with a lead plaintiff deadline of January 23, 2026 [4]. - Allegations include misleading statements regarding changes in payment timing to vendors, adversely affecting free cash flow and resulting in materially misleading financial reports [4].

Core Viewpoint - A class action securities lawsuit has been filed against Perrigo Company plc, alleging securities fraud that affected investors between February 27, 2023, and November 4, 2025 [1][2]. Group 1: Allegations of Fraud - The lawsuit claims that Perrigo's acquisition of the infant formula business from Nestlé was significantly underinvested in maintenance and operational improvements [2]. - It is alleged that Perrigo needed to incur substantial capital and operational expenditures beyond previously stated cost estimates to address issues in the infant formula business [2]. - The complaint points out significant manufacturing deficiencies in the facility related to the infant formula business [2]. - As a result of these issues, Perrigo's financial results, including earnings and cash flow, were reportedly overstated [2]. - The positive statements made by the defendants regarding the Company's business and prospects were claimed to be materially misleading and lacked a reasonable basis [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until January 16, 2026, to request appointment as lead plaintiff [3]. - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4].

Core Viewpoint - Perrigo Company is facing a class action lawsuit due to allegations of misleading investors about the value of its infant formula business, which has resulted in significant financial repercussions for the company [1][3]. Summary by Sections Company Overview - Perrigo Company (NYSE: PRGO) provides over-the-counter health and wellness solutions in the U.S., Europe, and internationally [1]. Class Action Details - The class period for the lawsuit is from February 27, 2024, to November 4, 2025 [1]. - The lawsuit was filed on behalf of all investors who acquired Perrigo securities during the class period [1]. Allegations - The complaint alleges that Perrigo failed to disclose several critical issues regarding its infant formula business: 1. Significant underinvestment in maintenance, operational improvements, and repairs [3]. 2. The need for substantial capital and operational expenditures beyond previously stated cost estimates to remediate the business [3]. 3. Significant manufacturing deficiencies in the infant formula facility [3]. 4. Overstated financial results, including earnings and cash flow, due to the above issues [3]. Financial Impact - On November 5, 2025, Perrigo announced disappointing financial results for Q3 2025, leading to a reduction in its fiscal year 2025 outlook primarily due to dynamics in the infant formula industry [4]. - The company is initiating a strategic review of its infant formula business and reassessing a previously announced investment of $240 million in this area [4]. - Following this announcement, Perrigo's stock price fell by $5.09, or 25.2%, closing at $15.10 per share on November 5, 2025 [4].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Perrigo Company plc regarding a class action lawsuit due to alleged misleading statements and operational deficiencies related to the company's infant formula business [1][3]. Group 1: Allegations - The complaint alleges that during the class period from February 27, 2023, to November 4, 2025, Perrigo made materially false and misleading statements [3]. - Specific allegations include significant underinvestment in the infant formula business acquired from Nestlé, necessitating substantial capital and operational expenditures beyond stated estimates [3]. - The complaint also highlights significant manufacturing deficiencies in the infant formula facility, leading to overstated financial results, including earnings and cash flow [3]. Group 2: Class Action Details - Shareholders who purchased PRGO shares during the specified class period are encouraged to register for the class action, with a deadline of January 16, 2026, to seek lead plaintiff status [4]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's progress [4]. - Participation in the case incurs no cost or obligation for the shareholders [4]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements that inflate stock prices [5].

Core Viewpoint - The article discusses a class action lawsuit against Perrigo Company plc, alleging violations of the Securities Exchange Act of 1934 due to misleading statements and undisclosed issues related to its acquisition of Nestlé's infant formula business [1][2]. Company Overview - Perrigo Company plc is involved in providing over-the-counter health and wellness solutions [1]. - The company acquired Nestlé's Gateway infant formula plant and the rights to the Good Start® brand for $170 million in November 2022 [1]. Allegations and Financial Impact - The lawsuit claims that Perrigo's executives made false statements regarding the condition of the acquired infant formula business, which suffered from underinvestment and significant operational deficiencies [1]. - On February 27, 2024, Perrigo disclosed additional costs of $35 million to $45 million for remediation, leading to a 50% decline in earnings per share compared to the previous year [1]. - Following further disclosures, Perrigo's stock price fell over 15% on February 27, 2024, nearly 10% on May 7, 2024, and more than 11% on August 6, 2025, due to ongoing issues with the infant formula business [1]. - On November 5, 2025, Perrigo announced a strategic review of its infant formula business and revised its fiscal year 2025 outlook, resulting in a stock price drop of over 25% [1]. Legal Process - Investors who purchased Perrigo securities during the class period (February 27, 2023, to November 4, 2025) can seek appointment as lead plaintiff in the class action lawsuit [1]. - The lead plaintiff will represent the interests of all class members and can select a law firm to litigate the case [1].

Core Insights - The health care sector is experiencing a trend of oversold stocks, presenting potential buying opportunities for undervalued companies [1][2] Group 1: Oversold Stocks - Larimar Therapeutics Inc (NASDAQ:LRMR) has an RSI of 29.9, with shares falling 12.1% to close at $3.12. The company reported a wider-than-expected quarterly loss but highlighted positive long-term data from a clinical study [3][8] - Perrigo Company PLC (NYSE:PRGO) also has an RSI of 29.9, with shares declining 1.7% to close at $13.61. The company reported mixed third-quarter results and lowered its FY25 adjusted EPS guidance, despite gaining market share in several categories [4][8] - ORIC Pharmaceuticals Inc (NASDAQ:ORIC) has an RSI of 29.6, with shares falling 4.5% to close at $10.65. The company has seen a 16% decline in stock price over the past month [5][8]